Immunohistochemical results showed, in all treated tumors, a significant increase in the intratumoral CD4+ and CD8+ T cells that are the major lymphocyte populations involved in the antitumor priming and tumor rejection in vivo in addition to a significant decrease in the intratumoral MDSCs (Figs. 3 and S1). Here, CD8A is linked to neoplasm.